PharmaLundensis AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
For the full year, net loss was SEK 3.29 million compared to SEK 2.61 million a year ago. Basic loss per share from continuing operations was SEK 0.11 compared to SEK 0.09 a year ago.